Yayınlar & Eserler

Yayın Ağı
Makaleler 36
Tümü (36)
SCI-E, SSCI, AHCI (27)
SCI-E, SSCI, AHCI, ESCI (34)
ESCI (7)
Scopus (30)
TRDizin (4)

1. Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

Ellez H. İ., SEMİZ H. S., EKİNCİ F., ERDOĞAN A. P., Kuş F., Karataş F., et al.
Journal of Bone Oncology , cilt.55, 2025 (SCI-Expanded, Scopus) identifier

2. Prognostic role of eIF2α protein in metastatic renal cell cancer patients

EKİNCİ F., MAVİLİ H. S., NEŞE N., ERDOĞAN A. P., Demir B., Oktay E., et al.
DISCOVER ONCOLOGY , cilt.16, sa.1, 2025 (SCI-Expanded) identifier identifier identifier

3. The Advanced Lung Cancer Inflammation Index: A Powerful and Independent Prognostic Factor in Metastatic Gastric Cancer

AVCI T., ŞAHBAZLAR M., EKİNCİ F., ERDOĞAN A. P.
Medicina (Lithuania) , cilt.61, sa.11, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

4. IPI score as a new prognostic index in extensive stage small cell lung cancer

AĞAOĞLU A. B., EKİNCİ F., ŞAHBAZLAR M., ERDOĞAN A. P.
PEERJ , cilt.13, 2025 (SCI-Expanded, Scopus) identifier identifier

5. Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer

AĞAOĞLU A. B., ERDOĞAN A. P., EKİNCİ F., ŞAHBAZLAR M., Tekustun G. N., Tanriverdi O., et al.
Medicina (Lithuania) , cilt.61, sa.11, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

6. SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer

Akar H., EKİNCİ F., ERDOĞAN A. P., ŞAHBAZLAR M.
Medicina (Lithuania) , cilt.61, sa.11, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

7. SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab

Kolkıran N., ERDOĞAN A. P., ŞAHBAZLAR M., Taş S., Gököz Doğu G., CANASLAN K., et al.
Current Oncology , cilt.32, sa.10, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

8. Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study

Acar O., AĞAOĞLU A. B., ŞAHBAZLAR M., EKİNCİ F., ERDOĞAN A. P.
Journal of Clinical Medicine , cilt.14, sa.20, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

9. The Psychosocial Burden of Breast Cancer: A Cross-Sectional Study of Associations Between Sleep Quality, Anxiety, and Depression in Turkish Women

Acar Ö., Goksel G., OZAN E., ALTUNBAŞ A. A., KARAKAYA M. S., EKİNCİ F., et al.
Journal of Clinical Medicine , cilt.14, sa.19, 2025 (SCI-Expanded) identifier identifier identifier identifier

10. Postoperative CA-125 as a Prognostic Marker for Overall Survival in Ovarian Cancer

AĞAOĞLU A. B., EKİNCİ F., ERDOĞAN A. P., ŞAHBAZLAR M., Turkmen E.
Journal of the College of Physicians and Surgeons Pakistan , cilt.35, sa.9, ss.1128-1134, 2025 (SCI-Expanded) identifier identifier identifier

11. The Effect of HER2 Status on Gastric Cancer Survival and the Clinical Implications of the HER2-Low Definition: A Retrospective Study

Uzun M., Gokcek S., Kilinc M., Ekinci F., Avcı T., Erdogan A. P., et al.
Medicina , sa.61091675, ss.1-12, 2025 (SCI-Expanded)

12. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Sahin T. K., DİZDAR Ö., Efil S. C., Sendur M. A. N., et al.
Cancers , cilt.17, sa.17, 2025 (SCI-Expanded) identifier identifier identifier identifier

13. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

Akturk Esen S., Seven I., Akdere Ates G., Colak R., Kinikoglu O., Akay Hacan B., et al.
ANTI-CANCER DRUGS , cilt.36, sa.7, ss.575-582, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

14. Isolated Synchronous Splenic Metastasis from Endometrial Carcinoma: Case Report

Kolkiran N., Avsar M. G., Ates G. A., ŞAHBAZLAR M., MAVİLİ H. S., ERDOĞAN A. P.
DUZCE MEDICAL JOURNAL , cilt.27, sa.2, ss.227-229, 2025 (ESCI, Scopus, TRDizin) identifier identifier identifier

15. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Gokcek S., ÜNEK İ. T., Sahin T. K., DİZDAR Ö., et al.
Journal of Clinical Medicine , cilt.14, sa.16, 2025 (SCI-Expanded) identifier identifier identifier identifier

16. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations

Alan O., Telli T. A., Akbas S., Isik S., Çavdar E., Karaboyun K., et al.
Medicina (Lithuania) , cilt.61, sa.7, 2025 (SCI-Expanded) identifier identifier identifier

17. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.
Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded) identifier identifier identifier

18. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.
Turkish Journal of Clinics and Laboratory , cilt.16, sa.2, ss.255-262, 2025 (Hakemli Dergi) identifier

19. Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

Ozgun A., Mustafayev F. N. A., Dogan I., Vatansever S., Eryilmaz M. K., ERDOĞAN A. P., et al.
Molecular and Clinical Oncology , cilt.22, sa.6, 2025 (ESCI) identifier identifier identifier identifier

20. Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer

AVCI T., ŞAHBAZLAR M., EKİNCİ F., ERDOĞAN A. P.
Current Oncology , cilt.32, sa.3, 2025 (SCI-Expanded) identifier identifier identifier

21. Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy

Eniseler E. B., Çetin B., EKİNCİ F., ERDOĞAN A. P., ŞAHBAZLAR M.
Clinical and Translational Oncology , 2025 (SCI-Expanded) identifier identifier identifier identifier

22. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., AVCI T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY , cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

23. Positive Lymph Node Ratio as a new prognostic score in Geriatric patients with operated gastric cancer

Acar O., Balcik O. Y., Ürün M., AVCI T., ŞAHBAZLAR M., ERDOĞAN A. P.
Heliyon , cilt.10, sa.19, 2024 (SCI-Expanded) identifier identifier identifier

24. Biases and Reluctances Causing Cancer Patients in Dilemma for COVID-19 Vaccination

Ekinci F., ERDOĞAN A. P., Göksel G.
Bangladesh Journal of Medical Science , cilt.23, sa.2, ss.345-354, 2024 (ESCI) identifier identifier

25. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yildirim H. C., Kutlu Y., Mutlu E., Aykan M. B., Korkmaz M., Yalcin S., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

26. HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer

Acar O., Ayhan M., Demir B., Ekinci F., Aytac A., ERDOĞAN A. P.
Journal of the College of Physicians and Surgeons Pakistan , cilt.33, sa.12, ss.1405-1409, 2023 (SCI-Expanded) Creative Commons License identifier identifier identifier

27. Real-Life Data of Neoadjuvant Chemotherapy in Breast Cancer: Aegean Region Experience

ERDOĞAN A. P., EKİNCİ F., Ozveren A., Eniseler E. B., Demir B., ŞAHBAZLAR M.
EUROPEAN JOURNAL OF THERAPEUTICS , cilt.29, sa.2, ss.123-127, 2023 (ESCI, TRDizin) Sürdürülebilir Kalkınma identifier

28. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., BAYRAM E., Demirel B. C., et al.
FUTURE ONCOLOGY , cilt.19, ss.727-736, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

29. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

GÜRBÜZ M., Kutlu Y., Akkus E., KÖKSOY E. B., Kose N., Oven B. B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

30. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

Yildirim H. C., Mutlu E., Chalabiyev E., Ozen M., Keskinkilic M., ÖN S., et al.
BREAST , cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

31. Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study

ERDOĞAN A. P., EKİNCİ F., AKÇALI S., Goksel G.
JOURNAL OF INFECTION AND CHEMOTHERAPY , cilt.28, sa.9, ss.1310-1316, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

32. Level of COVID-19 fear in cancer patients

ERDOĞAN A. P., EKİNCİ F., Acar O., Goksel G.
MIDDLE EAST CURRENT PSYCHIATRY-MECPSYCH , cilt.29, sa.1, 2022 (ESCI, Scopus) Sürdürülebilir Kalkınma identifier identifier

33. Retinal Detachment Due to Choroidal Metastasis in a Patient with Lung Cancer

EKİNCİ F., DİRİCAN A., ALTINIŞIK M., YILMAZ OVALI G., ERDOĞAN A. P., GÖKSEL ÖZTÜRK G.
İzmir Tepecik Eğitim Hastanesi Dergisi , cilt.31, sa.2, ss.269-271, 2021 (TRDizin) identifier

34. Molecular Subtypes of Breast Cancer in Women ≤35 years and >35 years: Does Age Matter?

Ozisik H., ERDOĞAN A. P., Surmeli Z. G., EKİNCİ F., DURUSOY ONMUŞ İ. R., Karaca B.
CLINICAL CANCER INVESTIGATION JOURNAL , cilt.10, sa.3, ss.112-116, 2021 (ESCI) Sürdürülebilir Kalkınma identifier

35. Retrospective analysis of patients with relapsed or refractory testicular nonseminous germ cell tumors treated with autologous stem cell transplantation

Yilmaz F., Soyer N., Uslu R., ERDOĞAN A. P., Karaca B., SAYDAM G., et al.
INDIAN JOURNAL OF CANCER , cilt.54, sa.2, ss.415-420, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

36. Pazopanib: a novel treatment option for aggressive fibromatosis

Bulut G., Ozluk A., ERDOĞAN A. P., Uslu R., Elmas N., Karaca B.
CLINICAL SARCOMA RESEARCH , cilt.6, ss.1-4, 2016 (ESCI) Sürdürülebilir Kalkınma identifier identifier
Metrikler

Yayın

140

Yayın (WoS)

50

Yayın (Scopus)

48

H-İndeks (WoS)

8

Atıf (Scopus)

202

H-İndeks (Scopus)

7

Proje

19

Tez Danışmanlığı

3

Açık Erişim

10
BM Sürdürülebilir Kalkınma Amaçları